Mosaic Q3 10-Q: Cash Down to $151, Going Concern Stands, Liabilities Near $8M
CPMV sits 41% above its 52-week low of $0.054 on light trading volume (0.1× avg).
Summary
Mosaic's Q3 2026 10-Q shows $151 of cash, a $518,741 nine-month net loss and $7.99 million of liabilities, with management repeating that it cannot fund operations for the next twelve months without new capital.
Key Events · Earnings and Guidance · CPMV
-
Cash Nearly Exhausted at Quarter End
Cash and cash equivalents stood at $151 at September 30, 2026, down from $3,622 at December 31, 2025, with no revenue generated.
-
Going Concern Doubt Reiterated
Management states that cash on hand will not satisfy operational and capital requirements through twelve months from the filing date and that it has no current arrangements for additional financing.
-
Liabilities Swell to $7.99 Million
Total liabilities rose to $7,994,912 from $7,495,902 at December 31, 2025, driven by accrued compensation of $4,608,023 and convertible notes of $1,520,695; stockholders' deficit widened to $7,994,761.
-
Nine-Month Loss of $518,741
Net loss for the nine months ended September 30, 2026 was $518,741, or $0.07 per share, on operating expenses of $454,013.
Analysis · CPMV · Life Sciences
The going-concern warning is not boilerplate: Mosaic ended September 30, 2026 with $151 of cash against $7.99 million of liabilities, leaving it unable to fund operations without new capital, and it says it has no financing arrangements in place. The only fresh business item is a services deal with Oncotelic worth $10,000 a month, which does not change the funding picture. Existing holders face substantial dilution if equity is raised, and the convertible notes convert at a discount to the next financing price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPMV was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $550.4K. The 52-week trading range was $0.05 to $1.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.